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Abstract Scleroderma is a female-prevalent autoimmune
disease of unclear etiology. Two fundamental gender differ-
ences, skewed X-chromosome inactivation (XCI) and
pregnancy-related microchimerism, have been implicated
in scleroderma. We investigated the XCI patterns of female
scleroderma patients and the parental origin of the inactive X
chromosome in those patients having skewed XCI patterns
(>80%). In addition, we investigated whether a correlation
exists between XCI patterns and microchimerism in a well-
characterized cohort. About 195 female scleroderma patients
and 160 female controls were analyzed for the androgen
receptor locus to assess XCI patterns in the DNA extracted
from peripheral blood cells. Skewed XCI was observed in 67
(44.9%) of 149 informative patients and in 10 of 124 healthy
controls (8.0%) [odds ratio (OR)=9.3 (95% confidence
interval (CI) 4.3–20.6, P<0.0001)]. Extremely skewed
XCI (>90%) was present in 44 of 149 patients (29.5%)
but only in 3 of 124 controls (2.4%; OR=16.9; 95% CI
4.8–70.4, P<0.0001). Parental origin of the inactive X
chromosome was investigated for ten patients for whom
maternal DNAwas informative, and the inactive X chromo-
some was of maternal origin in eight patients and of paternal
origin in two patients. Skewed XCI mosaicism could be
considered as an important risk factor in scleroderma.
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Introduction
Scleroderma (systemic sclerosis, SSc) is an autoimmune
disease characterized by fibrosis and alterations in the
microvasculature [1]. Scleroderma is three to ten times
more prevalent in women than in men [2]. Most autoim-
mune diseases are more prevalent in females than in males
[3], and fundamental differences between male and female
biology, such as hormone status [4], pregnancy [5], and X-
chromosome inactivation [6, 7] have been proposed as the
underlying pathophysiological mechanisms leading to the
female prevalence of autoimmune diseases. Indeed, both
pregnancy-related microchimerism [8–11], and skewed
(i.e., not the expected 50:50 balance) X-inactivation
mosaicism [12] have been shown to be associated with
scleroderma.
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This study was performed to investigate the X-inactivation
patterns of female scleroderma patients along with the parental
origin of the inactive X chromosome in those patients with
extremely skewed X-inactivation. In addition, the correlation
between skewed X-inactivation and both maternal and fetal
microchimerism was examined in a well-characterized cohort
of scleroderma patients.
Materials and Method
DNA samples were obtained from 195 scleroderma patients
and 160 control women. Clinical characteristics of the
patients and controls have been published elsewhere [12,
13]. The ethics review boards at the participating institu-
tions approved the study protocol. Informed consent was
obtained from all subjects. The X-chromosome inactivation
status of the patients and controls was determined by
genotyping a highly polymorphic CAG repeat in the first
intron of the androgen receptor as previously described [12,
14]. Depending on the definition and quantitative accuracy
of the measurement method, a few percent to nearly one
fifth of apparently healthy women display skewed (i.e.,
non-random) patterns of X-inactivation. Whereas ratios in
the range of 50–79% are usually regarded as normal
variation, deviation from this range in 80–89% of cells is
defined as skewed, and above 90% of cells as extremely




Our data show that skewed X-chromosome inactivation
(>80%) was associated with disease. X-chromosome
inactivation status was informative in 94 of the 125
scleroderma patients (75%) and in 124 of the 160 controls
(78%). Only the individuals whose alleles resolved ade-
quately were included in the subsequent densitometric
analysis; thus, some of the heterozygous individuals were
considered as uninformative. Skewing in the range of 80–
89% was observed in 15 of the 94 patients (16.0%) but in
only 7 of the 124 controls (5.6%; P<0.0001; Table 1).
Extremely skewed X-inactivation (>90%) was observed in
17 of the 94 patients (18.1%) but in only 3 of the 124
controls (2.4%; P<0.0001). When the data from the present
and the previously published [12] studies were combined
(Table 1), of the total of 195 patients, 149 were informative
for the androgen receptor polymorphism. Skewed X-
inactivation was observed in 67 of 149 patients (44.9%)
but in only 10 of 124 healthy controls (8.0%). Expressed as
a risk factor for scleroderma, the odds ratio (OR) was 9.3
[95% confidence interval (CI) 4.3–20.6; P<.0001]. Numer-
ous studies conducted in different control populations
indicate that extremely skewed X-inactivation is a rare
event not exceeding 3–5% [15–17]. For the current study,
extremely skewed X-inactivation was present in 44 of 149
patients (29.5%) but in only 3 controls (2.4%), and the OR
was 16.9 (95% CI 4.8–70.4, P<0.0001).
Parental Origin of the Inactive X Chromosome
Nineteen patients with skewed X-inactivation for whom
maternal DNA was available were further analyzed to
determine the parental origin of the inactive X chromosome.
For this analysis, DNA samples from mothers of patients
were analyzed for the androgen receptor gene polymor-
phism, and informative results were obtained for ten patient–
mother pairs. For the remaining nine pairs, both the mother
and the daughter were heterozygous for the androgen
receptor polymorphism, thus providing no difference in
allele sizes. Therefore, it is not possible to determine the
parental origin of the alleles in the absence of information
regarding the paternal genotype. The inactive X chromo-
some was of maternal origin in eight patients and of paternal
origin in two patients. In three mothers of patients studied,
X-inactivation pattern was also skewed (Table 2). Interest-
ingly, the same allele was skewed in both the mothers and
the patients, and one mother had been diagnosed with an
autoimmune condition, namely temporal arteritis.
Table 1 Proportions of sclero-
derma patients and controls
with skewed X-inactivation
For comparison by χ2 ,
P<0.0001(both >80% skewing
and >90% skewing)









+90 17 (18.1%) 27 (49.1%) 44 (29.5%) 3 (2.4%)
80–89 15 (16.0%) 8 (14.5%) 23 (15.4%) 7 (5.6%)
70–79 15 (16.0%) 0 (0.0%) 15 (10.1%) 22 (17.7%)
60–69 24 (25.5%) 5 (9.1%) 29 (19.5%) 29 (23.4%)
50–59 23 (24.5%) 15 (27.3%) 38 (25.5%) 63 (50.8%)
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Evaluation of Skewed X-Inactivation for Correlation
with Microchimerism
Maternal and fetal microchimerism was investigated as
described previously [18]. We examined X-inactivation
ratios for correlation with microchimerism in a limited
number of patients for whom microchimerism data was also
available. We observed that among patients with more than
80% skewing, 7 of 12 (58.3%) tested positive for maternal
microchimerism and 8 of 14 (57.1%) for fetal micro-
chimerism (Table 3). In patients with random patterns of
X-inactivation, 10 of 15 (66.7%) were positive for maternal
microchimerism, and 14 of 25 patients were positive for
fetal microchimerism (56%). Neither maternal (P=0.7) nor
fetal microchimerism (P=1.0) correlated with skewed
X-inactivation.
Discussion
Autoimmune disorders affect more than 5% of the population,
and a high female prevalence is characteristic of most
autoimmune diseases including scleroderma, autoimmune
thyroid diseases, systemic lupus erythematosus, and Sjögren’s
syndrome [3]. Pregnancy-related microchimerism [10] and
skewed X-inactivation [12] have been proposed as potential
contributors to the pathophysiology of scleroderma. In this
study, we observed skewed X-inactivation patterns in a
significant proportion (34%) of women with scleroderma. Of
these women, approximately 18% displayed extreme skew-
ing (>90:10). This result is consistent with our previous
study [12] and indicates that skewed X-inactivation could be
a common finding in different population groups.
We do not know the cause of skewed X inactivation in
scleroderma, and probable mechanisms have been discussed in
the accompanying manuscript [19]. Among them, X-linked
lethal mutations, which would be compatible with life in
females because of X-inactivation mosaicism, are appealing
causative mechanism. If the cause of skewing is indeed X-
linked mutations, these should be inherited from the maternal
lineage unless they occur de novo during gametogenesis. We
therefore analyzed the parental origin of the inactive X
chromosome in 19 patient–mother pairs, and of the 10 pairs
with informative genotyping results, inactive X was found to
be of maternal origin in 8 pairs. This result is on the border of
statistical significance (P=0.055). Assuming this result holds,
we will be left with an interesting puzzle. Why are maternally
inherited X chromosomes more likely to be inactivated in
highly skewed patients? One possibility is that some X
chromosomes confer a selective disadvantage to both the
organism itself and the peripheral cells within the organism.
This precise situation has been documented in X-linked
immunodeficiency, where heterozygous (female) carriers
have high X-inactivation skew (because of natural selection
within the organism), whereas affected males have a survival
disadvantage [20]. When an X-encoded genotype is selec-
tively disadvantageous to cells, skew is an outcome. When an
X-encoded genotype is selectively disadvantageous to an
organism, preferential maternal inheritance is an outcome.
Together, this leads us to the hypothesis that some highly
Table 2 Parental origin of the inactive X chromosome in scleroderma
patients with skewed X-inactivation
Sample Degree of skewing Parental origin of
the inactive X chromosome
Patient 1 95 Maternal
Mother 1 95
Patient 2 95 Maternal
Mother 2 95
Patient 3 86 Maternal
Mother 3 88
Patient 4 100 Maternal
Mother 4 Not informative
Patient 5 90 Maternal
Mother 5 Not informative
Patient 6 90 Maternal
Mother 6 Not informative
Patient 7 85 Maternal
Mother 7 67
Patient 8 85 Maternal
Mother 8 58
Patient 9 85 Paternal
Mother 9 70
Patient 10 80 Paternal
Mother 10 70
Table 3 Proportion of mater-




Skewed (>80%) 12 tested 58.3% positive for MMc 14 tested 57.1% positive for FMc
7 positive 8 positive
5 negative 6 negative
Random (<80%) 15 tested 66.7% positive for MMc 25 tested 56.0% positive for FMc
10 positive 14 positive
5 negative 11 negative
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skewed patients have an X chromosome that would confer a
selective disadvantage on homozygotic women and on males.
Because scleroderma is the first disease in which pregnan-
cy-related microchimerism has been documented, we investi-
gated a subset of patients for whommicrochimerism data were
also available for correlation of skewed X-inactivation with
microchimerism. Neither maternal nor fetal microchimerism
was found to be correlated with skewed X-inactivation. In
conclusion, the two types of female mosaicism—skewed X-
inactivation and maternal/fetal microchimerism—appear to be
independent risk factors in scleroderma. One possible expla-
nation for these data is that mosaicism itself is an underlying
cause of scleroderma and, by extension, female-prevalent
autoimmune disease in general.
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